Interesting IMMU Put And Call For May 2014

Investors in Immunomedics, Inc. ( IMMU) saw new options become available this week, for the May 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IMMU options chain for the new May 2014 contracts and identified one put and one call contract of particular interest.

The put contract at the $5.00 strike price has a current bid of 75 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $5.00, but will also collect the premium, putting the cost basis of the shares at $4.25 (before broker commissions). To an investor already interested in purchasing shares of IMMU, that could represent an attractive alternative to paying $6.11/share today.

Because the $5.00 strike represents an approximate 18% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 74%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 15.00% return on the cash commitment, or 23.50% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for Immunomedics, Inc., and highlighting in green where the $5.00 strike is located relative to that history:

If you liked this article you might like

Kite Takeover by Gilead Lifts Biotech Stocks

Biotech Movers: Immunomedics, Aerie, Exelixis

Immunomedics, Seattle Genetics Scrap License Deal

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Bullish and Bearish Reversals for This Week